AptarGroup says US antitrust case over nasal spray belongs in New York
( December 16, 2025, 23:31 GMT | Official Statement) -- MLex Summary: AptarGroup moved to dismiss ARS Pharmaceuticals Operations’ US antitrust case illegally limiting competition to its emergency-use single-dose intranasal spray system, arguing that the issues presented should be determined as part of a previously filed New York case. AptarGroup said that the court should dismiss the California case under the first-to-file rule or transfer the case. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.